logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
B

Barbara Haber

Merck and Co.
H指数:38
被引数:5,484

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

An Analysis of Cytomegalovirus-Specific Cell-Mediated Immunity in a Phase 3, Randomized, Placebo-Controlled Trial of Letermovir Prophylaxis in Cytomegalovirus-Seropositive Recipients of an Allogeneic Hematopoietic Cell Transplant

对一例异基因造血细胞移植巨细胞病毒血清学阳性受者中进行Letermovir预防的III期、随机、安慰剂对照试验中巨细胞病毒特异性细胞介导免疫的分析

CLINICAL INFECTIOUS DISEASES
IF7.3
2025-12-010
PRE
Papanicolaou, Genovefa A.; Dadwal, Sanjeet S.; Ariza-Heredia, Ella J.; Chiusolo, Patrizia; Morris, Michele, I; Tholouli, Eleni; Haber, Barbara; Broyde, Natalya; Gilbert, Christopher L.; Badshah, Cyrus
Hepatocellular Carcinoma Recurrence in Patients with Chronic Hepatitis C Infection Treated with Direct-Acting Antivirals: A Systematic Review and Meta-Analysis

慢性丙型肝炎感染患者接受直接抗病毒药物治疗后肝细胞癌复发：一项系统评价和Meta分析

Infectious Diseases and Therapy
IF5.3
2025-08-220
OAAI
Kristina Lindsley; Margaret Burroughs; Candido Hernandez-Lopez; Yi Wang; John Marcinak; Stephanie E. Chiuve; Barbara A. Haber; Jennifer Uyei; Soodabeh Navadeh; Giuseppe De Marco; Deanna D. Hill
Impact of kidney function on 200 days of antiviral prophylaxis for cytomegalovirus disease in CMV-seronegative recipients of CMV-seropositive donor kidneys Post hoc analysis of a randomized, phase 3 trial of letermovir versus valganciclovir prophylaxis

肾功能对CMV-seronegative受者接受CMV-seropositive供肾者肾脏后200天巨细胞病毒疾病抗病毒预防的影响：一项关于letermovir与valganciclovir预防的随机、III期试验的事后分析

American Journal of Transplantation
IF8.2
2025-07-210
PREAI
Klemens Budde; Nassim Kamar; Marta Crespo; Catherine B. Small; Nicole Stauffer; Natalya Broyde; Christopher L. Gilbert; Pamela Moise; Barbara Haber
Elbasvir/grazoprevir in children aged 3-18 years with chronic HCV genotype 1 or 4 infection: a pharmacokinetic modeling study
HEPATOLOGY COMMUNICATIONS
IF4.6
2023-03-015
OAAI
Gonzalez-Peralta, Regino P.; Wirth, Stefan; Squires, Robert H.; Mutschler, Frauke; Lang, Thomas; Pawlowska, Malgorzata; Sluzewski, Wojciech; Majda-Stanislawska, Ewa; Fischler, Bjorn; Balistreri, William F.; Jonas, Maureen M.; Blondet, Niviann; Rosenthal, Philip; Alkhouri, Naim; Romero, Rene; Grandhi, Anjana; Castronuovo, Patricia; Caro, Luzelena; Du, Lihong; Rosenbloom, Daniel I. S.; Haber, Barbara A.
Reinfection and Risk Behaviors After Treatment of Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy A Cohort Study
ANNALS OF INTERNAL MEDICINE
IF15.2
2022-09-0110
PRE
Grebely, Jason; Dore, Gregory J.; Altice, Frederick L.; Conway, Brian; Litwin, Alain H.; Norton, Brianna L.; Dalgard, Olav; Gane, Edward J.; Shibolet, Oren; Nahass, Ronald; Luetkemeyer, Anne F.; Peng, Cheng-Yuan; Iser, David; Gendrano, Isaias Noel; Kelly, Michelle M.; Hwang, Peggy; Asante-Appiah, Ernest; Haber, Barbara A.; Barr, Eliav; Robertson, Michael N.; Platt, Heather
Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial
EUROPEAN UROLOGY ONCOLOGY
IF9.3
2022-04-0120
PREAI
Rini, Brian I.; Atkins, Michael B.; Plimack, Elizabeth R.; Soulieres, Denis; McDermott, Raymond S.; Bedke, Jens; Tartas, Sophie; Alekseev, Boris; Melichar, Bohuslav; Shparyk, Yaroslav; Kondoh, Chihiro; Langiewicz, Przemyslaw; Wood, Lori A.; Hammers, Hans; Silber, Cynthia G.; Haber, Barbara; Jensen, Erin; Chen, Mei; Powles, Thomas
Efficacy and safety of elbasvir/grazoprevir for 8 or 12 weeks for hepatitis C virus genotype 4 infection: A randomized study
LIVER INTERNATIONAL
IF5.2
2020-03-228
PREAI
Asselah, Tarik; Pol, Stanislas; Hezode, Christophe; Loustaud-Ratti, Veronique; Leroy, Vincent; Ahmed, Si Nafa Si; Ozenne, Violaine; Bronowicki, Jean-Pierre; Larrey, Dominique; Tran, Albert; Alric, Laurent; Nguyen-Khac, Eric; Robertson, Michael N.; Hanna, George J.; Brown, Deborah; Asante-Appiah, Ernest; Su, Feng-Hsiu; Hwang, Peggy; Hall, Jessie Durrand; Guidoum, Amir; Hagen, Karin; Haber, Barbara A.; Talwani, Rohit; Serfaty, Lawrence
Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trial

Elbasvir/grazoprevir和sofosbuvir治疗丙型肝炎病毒基因型3感染并代偿期肝硬化: 一项随机试验

HEPATOLOGY
IF15.8
2018-04-1918
OAAI
Foster, Graham R.; Agarwal, Kosh; Cramp, Matthew E.; Moreea, Sulleman; Barclay, Stephen; Collier, Jane; Brown, Ashley S.; Ryder, Stephen D.; Ustianowski, Andrew; Forton, Daniel M.; Fox, Ray; Gordon, Fiona; Rosenberg, William M.; Mutimer, David J.; Du, Jiejun; Gilbert, Christopher L.; Asante-Appiah, Ernest; Wahl, Janice; Robertson, Michael N.; Barr, Eliav; Haber, Barbara

研究方向

暂未获取到该数据
M
Michael Robertson
H 指数:47论文数:200被引数:1.1万
P
Peggy Hwang
H 指数:23论文数:86被引数:2,063
P
Philip Rosenthal
H 指数:71论文数:1,181被引数:1.6万
J
Janice Wahl
H 指数:29论文数:161被引数:4,635
K
Kathleen B. Schwarz
H 指数:53论文数:357被引数:1.0万
J
Jean P. Molleston
H 指数:55论文数:264被引数:8,802
E
Eliav Barr
H 指数:55论文数:163被引数:2.0万
R
Regino P. González‐Peralta
H 指数:34论文数:132被引数:3,844
M
Michael R. Narkewicz
H 指数:55论文数:194被引数:8,845
K
Karen F. Murray
H 指数:46论文数:187被引数:9,852